Trial reportThe pharmacogenomics journal2020
OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.
Trial report in The pharmacogenomics journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia.European journal of pain (London, England) · 2026Trial
- Cancer pain.Nature reviews. Disease primers · 2026Review
- Review
- Decoding the mechanisms of acupuncture by neuroimaging: an integrated review from networks to molecules.Frontiers in human neuroscience · 2026Review
- Sleep-Disordered Breathing and Interactions with Opioids: A Narrative Review.Journal of clinical medicine · 2025Review
- Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder.Genetic epidemiology · 2025Article
- Genetic Variants inGenes · 2024Article
- A Commentary on "Effective Dose of Epidural Hydromorphone for Analgesia Following Caesarean Section in Using Modified Dixon Sequential Method" [Letter].Journal of pain research · 2024Article
- Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.BMC pharmacology & toxicology · 2023Article
- Effect of common OPRM1, COMT, SLC6A4, ABCB1, and CYP2B6 polymorphisms on perioperative analgesic and propofol demands on patients subjected to thyroidectomy surgery.Pharmacological reports : PR · 2023Article
- Rubbing Salt in the Wound: Molecular Evolutionary Analysis of Pain-Related Genes Reveals the Pain Adaptation of Cetaceans in Seawater.Animals : an open access journal from MDPI · 2022Article
- Progress, Challenges, and Prospects of Research on the Effect of Gene Polymorphisms on Adverse Reactions to Opioids.Pain and therapy · 2022Review
- Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota.The pharmacogenomics journal · 2022Article
- CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder.Frontiers in psychiatry · 2022Article
- Role of daytime variation in pharmaceutical effects of sufentanil, dezocine, and tramadol: A matched observational study.Frontiers in pharmacology · 2022Article
- Pharmacogenetics in Primary Headache Disorders.Frontiers in pharmacology · 2021Review
- Bioinformatics Analysis of Genes and Mechanisms in Postherpetic Neuralgia.Pain research & management · 2020Article
- Gene polymorphism impact on opioid analgesic usage.Journal of advanced pharmaceutical technology & researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Genetic polymorphisms have been shown to affect opioid requirement for pain relief. However, true genetic effect is often difficult to assess due to underlying pain conditions and placebo effects. The goal of this study was to understand how common polymorphisms affect opioid effects while controlling for these factors. A randomized, double-blind, placebo-controlled study was implemented to assess how opioid effects are modulated by COMT (rs6269, rs4633, rs4848, rs4680), OPRM1 (A118G), and OPRK1 (rs1051660, rs702764, rs16918875). One hundred and eight healthy subjects underwent experimental pain testing before and after morphine, butorphanol, and placebo (saline). Association analysis was performed between polymorphisms/haplotypes and opioid response, while correcting for race, gender, placebo effects, and multiple comparisons. Pressure pain was significantly associated with rs6269 and rs4633 following butorphanol. The AA genotype of rs4680 or A_T_C_A/ A_T_C_A (rs6269_rs4633_ rs4818_rs4680) diplotype of COMT, combined with the AG genotype of OPRM1 A118G, showed significantly increased pressure pain threshold from butorphanol. Opioid effects on pressure, ischemic, heat pain, and side effects were nominally associated with several SNPs and haplotypes. Effects were often present in one opioid but not the other. This indicates that these polymorphisms affect pain relief from opioids, and that their effects are opioid and pain modality specific.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.